An experienced life sciences doctor, researcher, inventor and entrepreneur, Dr. Hartwell will lead Mind Cure’s research efforts as it explores a range of new psychoactive substances and their therapeutic benefits
VANCOUVER, BC, Nov 10, 2020 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (“Mind Cure” or the “Corporation”) is pleased today to announce the hiring of Dr. Ryan Hartwell as the company’s Chief Science Officer. A trusted and respected leader in the life sciences community, Dr. Hartwell is also a successful entrepreneur and inventor with extensive regulatory experience in new drug and natural health product research and development. With a rigorous clinical research approach, Dr. Hartwell will lead all scientific efforts at Mind Cure alongside the company’s scientific advisory board.
“We have assembled a team of exceptional scientific advisors, and Dr. Hartwell is the perfect person to both lead them and guide our overall scientific efforts as we find new ways to treat mental health,” said Philip Tapley, Mind Cure Chairman, President, and CEO. “Dr. Hartwell will be integral to our goal of bringing new psychoactive and psychedelic drugs, treatments and technologies to market, with proper research and scientific validation.”
Dr. Hartwell has served on Mind Cure’s scientific advisory board for several months and is looking forward to the opportunity to further establish Mind Cure as a leader in the mental health revolution through research and science. “After a decade of researching solutions to prevent and treat physical scars, I am thrilled to join Mind Cure and the world-class team of scientists and researchers working towards a cure for psychological scarring,” said Dr. Ryan Hartwell. “From all that we have learned in studying psychedelics, the opportunity to chart a new path toward a better understanding and discovery of effective medicines provides tremendous potential to transform mental health and aging wellness.”
Dr. Hartwell will serve a key role in the advancement of Mind Cure’s science-first approach to research and product development and will lead the company’s efforts to explore a range of new psychoactive and psychedelic substances and their therapeutic benefits. Mind Cure is focused on developing safe and effective new drugs and treatments and bringing them to market with proper scientific validation and medical and regulatory compliance.
About Dr. Ryan Hartwell
Dr. Ryan Hartwell is an experienced scientist, inventor, researcher and entrepreneur. He earned his Ph.D. in Experimental Medicine at UBC, receiving the Vancouver Coastal Health Research Institute Award for Top Graduating Doctoral Student and Rising Star in Research. Dr. Hartwell also has a strong record of successful start-ups and is a co-inventor of FS2 and AI-001 cell therapy. Prior to undertaking his Ph.D., he cofounded ATS Biotech Inc., an advanced, biomedical wound care (medical device) company specializing in the development and manufacture of medical devices.
Dr. Hartwell holds a faculty position at UBC and is active managing teams and conducting research. He possesses first-hand experience in FDA, EU, HC, CFDA and Japan Regulatory filings for drug products, medical devices and natural health products, and has published 20 peer-reviewed articles, 26 presentation abstracts and holds four patents.
As an active member of the academic and life sciences community, Dr. Hartwell continues to lecture for the UBC Department of Surgery, as well as to lead investigator-forums and workshops at major local, national and international conferences. Prior to receiving his Ph.D., Dr. Hartwell attended the University of Ottawa, graduating with honours in Biochemistry and shortly thereafter as conducting research in Free Radicals in Medicine at the National University of Singapore under world-renowned researcher and industry leader, Professor Barry Halliwell.
The Company has granted a total of 500,000 stock options to Dr. Hartwell pursuant to the terms of his executive employment agreement and the Company’s incentive stock option plan (the “Plan”). The stock options are exercisable at a price of $0.64 and subject to the terms of the Plan. Additionally, 50,000 options were granted under the Plan to certain employees, consultants, or advisors of the Company at an exercise price of $0.71 and are also subject to the terms of the Plan.
About Mind Cure Health Inc.
Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure.
On Behalf of the Board of Directors
Philip Tapley, Chairman, President, and CEO
Phone: 1-888-593-8995
Forward-Looking Information
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mind Cure naming Dr. Ryan Hartwell as Chief Science Officer, Dr. Hartwell leading Mind Cure’s research efforts as it explores a range of new psychoactive substances and their therapeutic benefits, Mind Cure bringing new psychoactive and psychedelic drugs, treatments and technologies to market with proper research and scientific validation, and Dr. Hartwell’s role in the advancement of Mind Cure’s science-first approach to research and product development.
Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Dr. Hartwell will successfully lead Mind Cure’s science efforts and scientific advisory team; Mind Cure will be able to bring new psychoactive and psychedelic drugs, treatments and technologies to market, with proper research and scientific validation; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure’s industry and Mind Cure’s business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure’s investments, results of operations, financial condition and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; the addition of Dr. Hartwell may not help Mind Cure’s efforts to explore a range of new psychoactive and psychedelic substances and their therapeutic benefits, or the development of safe and effective new drugs and treatments with proper scientific validation and medical and regulatory compliance; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
Regulators authorized AstraZeneca’s coronavirus vaccine for use in adults throughout the European Union on Friday, amid criticism the bloc is not moving fast enough to vaccinate its population.
WASHINGTON (AP) — A former FBI lawyer was sentenced to probation for altering an email that the Justice Department relied on during its surveillance of an aide to President Donald Trump during the Russia investigation.
MADISON, Wis. (AP) — Democratic Gov. Tony Evers lashed out Friday at rival Republicans who tried to repeal his statewide mask mandate, saying killing the order would be a ridiculous move comparable to abolishing speed limits.
COLUMBIA, S.C. (AP) — As some conservatives in South Carolina celebrated getting a bill that would ban almost all abortions in the state past a legislative barrier and likely becoming law, they said they are not finished trying to end all abortions.
A Moscow court on Friday put the brother and several allies of Russian opposition leader Alexei Navalny under house arrest for two months as authorities sought to stymie more protests over the jailing of the top Kremlin foe.